"Researchers and Mobile Clinics Join Forces to Fight Cancer"
Bolt Biotherapeutics' chief medical officer, Edith Perez, is one of five cancer researchers featured in Stand Up to Cancer's new PSA campaign. Meanwhile, biotech venture funding fell to its lowest total since 2019 in Q1 2023, while California-based Acelyrin has filed to go public, a rare move in the current climate. In other news, the FDA rejected Eli Lilly's ulcerative colitis drug mirikizumab due to manufacturing issues.